Effects of Estrogen, an ERα Agonist and Raloxifene on Pressure Overload Induced Cardiac Hypertrophy
Open Access
- 5 December 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (12) , e50802
Abstract
The aim of this study was to investigate the effects of 17β-estradiol (E2), the selective ERα agonist 16α-LE2, and the selective estrogen receptor modulator (SERM) raloxifene on remodeling processes during the development of myocardial hypertrophy (MH) in a mouse model of pressure overload. Myocardial hypertrophy in ovariectomized female C57Bl/6J mice was induced by transverse aortic constriction (TAC). Two weeks after TAC, placebo treated mice developed left ventricular hypertrophy and mild systolic dysfunction. Estrogen treatment, but not 16α-LE2 or raloxifene reduced TAC induced MH compared to placebo. E2, 16α-LE2 and raloxifene supported maintenance of cardiac function in comparison with placebo. Nine weeks after induction of pressure overload, MH was present in all TAC groups, most pronounced in the raloxifene treated group. Ejection fraction (EF) was decreased in all animals. However, 16α-LE2 treated animals showed a smaller reduction of EF than animals treated with placebo. E2 and 16α-LE2, but not raloxifene diminished the development of fibrosis and reduced the TGFβ and CTGF gene expression. Treatment with E2 or 16α-LE2 but not with raloxifene reduced survival rate after TAC significantly in comparison with placebo treatment. In conclusion, E2 and 16α-LE2 slowed down the progression of MH and reduced systolic dysfunction after nine weeks of pressure overload. Raloxifene did not reduce MH but improved cardiac function two weeks after TAC. However, raloxifene was not able to maintain EF in the long term period.Keywords
This publication has 38 references indexed in Scilit:
- Plasma Levels of Transforming Growth Factor-β1 Reflect Left Ventricular Remodeling in Aortic StenosisPLOS ONE, 2009
- 17β-Estradiol inhibits matrix metalloproteinase-2 transcription via MAP kinase in fibroblastsCardiovascular Research, 2009
- Estrogen Inhibits Cardiac Hypertrophy: Role of Estrogen Receptor-β to Inhibit CalcineurinEndocrinology, 2008
- Both Estrogen Receptor Subtypes, α and β, Attenuate Cardiovascular Remodeling in Aldosterone Salt–Treated RatsHypertension, 2007
- Estrogen Receptor β Protects the Murine Heart Against Left Ventricular HypertrophyArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- The estrogen receptor-α agonist 16α-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive ratsCardiovascular Research, 2005
- Estrogen receptor-β mediates male-female differences in the development of pressure overload hypertrophyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Raloxifene Prevents Cardiac Hypertrophy and Dysfunction in Pressure-Overloaded MiceHypertension, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998